Liver-Directed Adeno-Associated Virus-Mediated Gene Therapy for Mucopolysaccharidosis Type VI.
Journal
NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
medline:
1
7
2022
pubmed:
1
7
2022
entrez:
6
2
2024
Statut:
ppublish
Résumé
Gene Therapy for Mucopolysaccharidosis Type VIIn this open-label gene therapy study, infusions for MPS type VI occurred without severe adverse events. In the high-dose cohort, serum active arylsulfatase B reached 30% to 100% of normal. A modest urinary GAG increase did not require reintroduction of enzyme replacement therapy. Clinical deterioration was not noted for up to 2 years after therapy.
Identifiants
pubmed: 38319253
doi: 10.1056/EVIDoa2200052
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM